儿童炎症性肠病的研究现状及展望
收稿日期: 2023-10-07
网络出版日期: 2023-11-08
基金资助
国家重点研发计划(2022YFC2703603);首都卫生发展科研专项(2022-2-2094);北京市医院管理中心“登峰”人才培养计划(DFL20221003)
An analysis of the present status and future prospects of pediatric inflammatory bowel disease
Received date: 2023-10-07
Online published: 2023-11-08
吴捷 , 张添卓 . 儿童炎症性肠病的研究现状及展望[J]. 临床儿科杂志, 2023 , 41(11) : 801 -807 . DOI: 10.12372/jcp.2023.23e0957
Pediatric inflammatory bowel disease (PIBD) refers to a group of chronic and recurrent intestinal inflammatory diseases with unidentified cause. The complexity of its pathogenesis presents ongoing challenges in diagnosis and treatment. In recent years, there has been a noticeable increase in the prevalence of IBD among children both domestically and internationally, which has aroused widespread concern among pediatricians. This article aims to provide a comprehensive overview of the pathogenesis in pediatric IBD, a turbo-charged treat to target strategy in IBD, as well as the transition of management in adolescents with IBD. Its findings can serve as a valuable reference for Chinese pediatricians engaged in IBD research.
| [1] | Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease[J]. J Crohns Colitis, 2014, 8(10): 1179-1207. |
| [2] | Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of paediatric ulcerative colitis, part 1: ambulatory care-an evidence-based guideline from European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition[J]. J Pediatr Gastroenterol Nutr, 2018, 67(2): 257-291. |
| [3] | Birimberg-Schwartz L, Zucker DM, Akriv A, et al. Development and validation of diagnostic criteria for IBD subtypes including IBD-unclassified in children: a multicentre study from the pediatric IBD Porto group of ESPGHAN[J]. J Crohns Colitis, 2017, 11(9): 1078-1084. |
| [4] | Benchimol EI, Fortinsky KJ, Gozdyra P, et al. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends[J]. Inflamm Bowel Dis, 2011, 17(1): 423-439. |
| [5] | Kuenzig ME, Fung SG, Marderfeld L, et al. Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: systematic review[J]. Gastroenterology, 2022, 162(4): 1147-1159. |
| [6] | Windsor JW, Buie M, Coward S, et al. A28 relative rates of ulcerative colitis to Crohn’s disease: parallel epidemiologies in newly vs. highly industrialized countries[J]. Journal of the Canadian Association of Gastroenterology, 2020, 3(Supplement_1): 34-35. |
| [7] | Kugathasan S, Baldassano RN, Bradfield JP, et al. Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease[J]. Nat Genet, 2008, 40(10): 1211-1215. |
| [8] | Muise AM, Snapper SB, Kugathasan S. The age of gene discovery in very early onset inflammatory bowel disease[J]. Gastroenterology, 2012, 143(2): 285-288. |
| [9] | Bequet E, Sarter H, Fumery M, et al. Incidence and phenotype at diagnosis of very-early-onset compared with later-onset paediatric inflammatory bowel disease: a population-based study [1988-2011][J]. J Crohns Colitis, 2017, 11(5): 519-526. |
| [10] | Ong C, Aw MM, Liwanag MJ, et al. Rapid rise in the incidence and clinical characteristics of pediatric inflammatory bowel disease in a South-East Asian cohort in Singapore, 1994-2015[J]. J Dig Dis, 2018, 19(7): 395-403. |
| [11] | Turpin W, Goethel A, Bedrani L, et al. Determinants of IBD heritability: genes, bugs, and more[J]. Inflamm Bowel Dis, 2018, 24(6): 1133-1148. |
| [12] | Suarez RG, Osornio-Vargas AR, Wine E. Ambient air pollution and pediatric inflammatory bowel diseases: an updated scoping review[J]. Dig Dis Sci, 2022, 67(9): 4342-4354. |
| [13] | Forbes JD, Van Domselaar G, Bernstein CN. Microbiome survey of the inflamed and noninflamed gut at different compartments within the gastrointestinal tract of inflammatory bowel disease patients[J]. Inflamm Bowel Dis, 2016, 22(4): 817-825. |
| [14] | Parada Venegas D, De la Fuente MK, Landskron G, et al. Corrigendum: short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases[J]. Front Immunol, 2019, 10: 1486. |
| [15] | Di Vincenzo F, Puca P, Lopetuso LR, et al. Bile acid-related regulation of mucosal inflammation and intestinal motility: from pathogenesis to therapeutic application in IBD and microscopic colitis[J]. Nutrients, 2022, 14(13): 2664. |
| [16] | Kurilshikov A, Wijmenga C, Fu J, et al. Host genetics and gut microbiome: challenges and perspectives[J]. Trends Immunol, 2017, 38(9): 633-647. |
| [17] | Flannigan KL, Geem D, Harusato A, et al. Intestinal antigen-presenting cells: key regulators of immune homeostasis and inflammation[J]. Am J Pathol, 2015, 185(7): 1809-1819. |
| [18] | Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD[J]. Gastroenterology, 2021, 160(5): 1570-1583. |
| [19] | Plevris N, Lees CW. Disease monitoring in inflammatory bowel disease: evolving principles and possibilities[J]. Gastroenterology, 2022, 162(5): 1456-1475. |
| [20] | Kuharic M, Krugliak Cleveland N, Candela N, et al. P042 Early versus later use of vedolizumab In IBD: patient characteristics and treatment patterns in the real world (RALEE)[J]. Am J Gastroenterol, 2021, 116(Suppl 1): S11. |
| [21] | Feuerstein JD, Nguyen GC, Kupfer SS, et al. American gastroenterological association institute guideline on therapeutic drug monitoring in inflammatory bowel disease[J]. Gastroenterology, 2017, 153(3): 827-834. |
| [22] | Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children[J]. Gastroenterology, 2007, 132(3): 863-873. |
| [23] | Hyams J, Damaraju L, Blank M, et al. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis[J]. Clin Gastroenterol Hepatol, 2012, 10(4): 391-399. |
| [24] | Papamichael K, Afif W, Drobne D, et al. Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives[J]. Lancet Gastroenterol Hepatol, 2022, 7(2): 171-185. |
| [25] | Vvan Rheenen PF, Aloi M, Assa A, et al. The medical management of paediatric Crohn's disease: an ECCO-ESPGHAN guideline update[J]. J Crohns Colitis, 2020-jjaa161. |
| [26] | Cheifetz AS, Abreu MT, Afif W, et al. A comprehensive literature review and expert consensus statement on therapeutic drug monitoring of biologics in inflammatory bowel disease[J]. Am J Gastroenterol, 2021, 116(10): 2014-2025. |
| [27] | Venkatesh K, Cohen M, Evans C, et al. Feasibility of confocal endomicroscopy in the diagnosis of pediatric gastrointestinal disorders[J]. World J Gastroenterol, 2009, 15(18): 2214-2219. |
| [28] | Miele E, Shamir R, Aloi M, et al. Nutrition in pediatric inflammatory bowel disease: a position paper on behalf of the Porto inflammatory bowel disease group of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition[J]. J Pediatr Gastroenterol Nutr, 2018, 66(4): 687-708. |
| [29] | Bischoff SC, Bager P, Escher J, et al. ESPEN guideline on clinical nutrition in inflammatory bowel disease[J]. Clin Nutr, 2023, 42(3): 352-379. |
| [30] | Sarbagili-Shabat C, Albenberg L, Van Limbergen J, et al. A novel UC exclusion diet and antibiotics for treatment of mild to moderate pediatric ulcerative colitis: a prospective open-label pilot study[J]. Nutrients, 2021, 13(11): 3736. |
| [31] | Radziszewska M, Smarkusz-Zarzecka J, Ostrowska L, et al. Nutrition and supplementation in ulcerative colitis[J]. Nutrients, 2022, 14(12): 2469. |
| [32] | Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of paediatric ulcerative colitis, part 2: acute severe colitis-an evidence-based consensus guideline from the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition[J]. J Pediatr Gastroenterol Nutr, 2018, 67(2): 292-310. |
| [33] | Nakase H, Uchino M, Shinzaki S, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020[J]. J Gastroenterol, 2021, 56(6): 489-526. |
| [34] | Atia O, Shavit-Brunschwig Z, Mould DR, et al. Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study[J]. Lancet Gastroenterol Hepatol, 2023, 8(1): 31-42. |
| [35] | Singh N, Rabizadeh S, Jossen J, et al. Multi-center experience of vedolizumab effectiveness in pediatric inflammatory bowel disease[J]. Inflamm Bowel Dis, 2016, 22(9): 2121-6. |
| [36] | Dayan JR, Dolinger M, Benkov K, et al. Real world experience with ustekinumab in children and young adults at a tertiary care pediatric inflammatory bowel disease center[J]. J Pediatr Gastroenterol Nutr, 2019, 69(1): 61-67. |
| [37] | Wlaz?o M, Kierku? J. Dual biologic therapy for the treatment of pediatric inflammatory bowel disease: a review of the literature[J]. J Clin Med, 2022, 11(7). |
| [38] | Panés J, Loftus EV, Higgins PDR, et al. Induction and maintenance treatment with upadacitinib improves health-related quality of life in patients with moderately to severely active ulcerative colitis: phase 3 study results[J]. Inflamm Bowel Dis, 2023, 29(9): 1421-1430. |
| [39] | D'Haens G, Panés J, Louis E, et al. Upadacitinib was efficacious and well-tolerated over 30 months in patients with Crohn's disease in the celest extension study[J]. Clin Gastroenterol Hepatol, 2022, 20(10): 2337-2346.. |
| [40] | Collen LV. Rapid clinical remission with upadacitinib in a pediatric patient with refractory Crohn's disease[J]. Inflamm Bowel Dis, 2023, 29(7): 1175-1176. |
| [41] | Moore H, Dubes L, Fusillo S, et al. Tofacitinib therapy in children and young adults with pediatric-onset medically refractory inflammatory bowel disease[J]. J Pediatr Gastroenterol Nutr, 2021, 73(3): e57-e62. |
| [42] | Kassam Z, Lee CH, Yuan Y, et al. Fecal microbiota transplantation for clostridium difficile infection: systematic review and meta-analysis[J]. Am J Gastroenterol, 2013, 108(4): 500-508. |
| [43] | 黄瑛, 王玉环. 粪菌移植治疗儿童炎症性肠病[J]. 中华实用儿科临床杂志, 2017, 32(7): 491-493. |
| [44] | Tan P, Li X, Shen J, et al. Fecal microbiota transplantation for the treatment of inflammatory bowel disease: an update[J]. Front Pharmacol, 2020, 11: 574533. |
| [45] | Reider S, Binder L, Fürst S, et al. Hematopoietic stem cell transplantation in refractory Crohn's disease: should it be considered?[J]. Cells, 2022, 11(21): 3436. |
| [46] | Liang J, Zhang H, Wang D, et al. Allogeneic mesenchymal stem cell transplantation in seven patients with refractory inflammatory bowel disease[J]. Gut, 2012, 61(3): 468-469. |
| [47] | Bollegala N, Brill H, Marshall JK. Resource utilization during pediatric to adult transfer of care in IBD[J]. J Crohns Colitis, 2013, 7(2): e55-60. |
| [48] | Menon T, Afzali A. Inflammatory bowel disease: a practical path to transitioning from pediatric to adult care[J]. Am J Gastroenterol, 2019, 114(9): 1432-1440. |
| [49] | Sexton KA, Walker JR, Graff LA, et al. Evidence of bidirectional associations between perceived stress and symptom activity: a prospective longitudinal investigation in inflammatory bowel disease[J]. Inflamm Bowel Dis, 2017, 23(3): 473-483. |
/
| 〈 |
|
〉 |
沪公网安备 31011002000392号
